SCHEMBL7538564

SCHEMBL7538564

Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1I

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
NT5E P21589 1/20 0.61
HIF1A Q16665 1/20 0.61
ADORA2A P29274 4/20 0.61
ADORA3 P0DMS8 4/20 0.61
SLC29A1 Q99808 2/20 0.61
ADORA2B P29275 3/20 0.60
CYP2C19 P33261 1/20 0.59
HPGD P15428 1/20 0.59
ADORA1 P30542 2/20 0.58
DPP4 P27487 1/20 0.58
MEN1 O00255 1/20 0.58
SLC28A1 O00337 1/20 0.58
MAP3K7 O43318 1/20 0.58
SLC28A2 O43868 1/20 0.58
GAPDH P04406 1/20 0.58
MAPK1 P28482 1/20 0.58
STAT6 P42226 1/20 0.58
PI4KA P42356 1/20 0.58
KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2014081 0.88 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL3970946 0.88 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL5033515 0.88 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL899617 0.88 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL6663083 0.88 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL16555404 0.88 LMNA (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL11481461 0.87 LMNA (0.61) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL62505 0.87 CYP2C19 (0.62) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL2424283 0.87 LMNA (0.64) LMNANT5EHIF1AADORA2AADORA3
SCHEMBL7535713 0.87 HPGD (0.62) LMNANT5EHIF1AADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6288221-B1 REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES DUKE UNIVERSITY 2001-09-11 US claimed
US-20020177695-A1 Nucleic acid probes and methods DUKE UNIVERSITY 2002-11-28 US disclosed
WO-2002044196-A1 METHODS AND REAGENTS FOR INTRODUCING A SULFHYDRYL GROUP INTO THE 5'-TERMINUS OF RNA UNIVERSITY OF MASSACHUSETTS (US) 2002-06-06 WO disclosed
US-6288221-B1 REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES DUKE UNIVERSITY 2001-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177695-A1 Nucleic acid probes and methods NUDT1, NT5C3B, NT5C2 LMNA 1665/4885NT5E 9/4885HIF1A 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.